<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862698</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.149</article-id><article-id pub-id-type="other">O0014</article-id><article-id pub-id-type="pii">S0924933824001494</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>Oral Communication</subject></subj-group></article-categories><title-group><article-title>Significant beneficial effects of 12-weeks add-on yoga therapy on antipsychotic-stabilized schizophrenia patients through epigenetic modulation: novel findings from a randomized controlled study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Debnath</surname><given-names>M.</given-names></name><xref rid="aff0040" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor0010" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mullapudi</surname><given-names>T.</given-names></name><xref rid="aff0040" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Govindaraj</surname><given-names>R.</given-names></name><xref rid="aff0041" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Raj</surname><given-names>P.</given-names></name><xref rid="aff0042" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Varambally</surname><given-names>S.</given-names></name><xref rid="aff0042" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff0040">
<sup>1</sup>Human Genetics</aff><aff id="aff0041">
<sup>2</sup>Neurophysiology</aff><aff id="aff0042">
<sup>3</sup>Psychiatry, National Institute of Mental Health and Neurosciences, <city>Bangalore</city>, <country>
India</country></aff><author-notes><corresp id="cor0010"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="123">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S47</fpage><lpage>S48</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824001494a.pdf"/><abstract><sec id="sec0055"><title>Introduction</title><p>Complementary and alternative therapy, especially yoga, is emerging as an important treatment modality for various complex disorders. Yoga therapy has reportedly been demonstrated to exhibit clinical benefits in schizophrenia. However, the modulatory effects of yoga therapy on the pathobiological pathways of schizophrenia are inadequately explored. Immune dysregulation is a widely recognized etiopathological construct of schizophrenia. It is not precisely known whether yoga therapy can modulate the expression of immune molecules by regulating gene expression and epigenetic processes in schizophrenia.</p></sec><sec id="sec0056"><title>Objectives</title><p>To understand the impact of 12-weeks add-on yoga therapy on the immune-inflammatory pathway in schizophrenia by examining plasma levels and gene expression levels of cytokines and complement proteins as well as by profiling promoter DNA methylation pattern of genes coding for cytokines and complement proteins.</p></sec><sec id="sec0057"><title>Methods</title><p>Fifty-seven schizophrenia patients fulfilling DSM-V criteria were recruited into the study and randomized into Yoga therapy (n=28) and waitlist control (n=29) groups. Plasma levels of IL-1&#x003b2;, IL-6, IL-10, IL-17, C1q, C2, C3, C4, C5, C5a, Factor B and Factor H by Multiplex Suspension Assay, quantification of gene expression of <italic toggle="yes">Il1b, Il6, Il10, IL17, C3, C4</italic> and <italic toggle="yes">C5</italic> genes by quantitative PCR and promoter DNA methylation of <italic toggle="yes">Il1b, Il6, Il10, Il17, C3, C4</italic> and <italic toggle="yes">C5</italic> genes by pyrosequencing were carried out in all the study participants.</p></sec><sec id="sec0058"><title>Results</title><p>Plasma levels of IL-1&#x003b2; (Z score= 2.42, p=0.02) dropped significantly and C2 (Z score= 2.24, p=0.03) levels increased after 12-weeks of yoga therapy. The expression of <italic toggle="yes">Il1b</italic> (Z score=2.45, p=0.01) and <italic toggle="yes">Il6</italic> (Z score=2.07, p=0.04) genes were significantly downregulated, while the levels of <italic toggle="yes">C4</italic> (Z score=2.23, p=0.03) gene was upregulated in schizophrenia patients of yoga therapy group.&#x000a0;Two CpG sites in the promoter region of <italic toggle="yes">Il1b</italic> (all p&#x02264;0.05) and <italic toggle="yes">Il6</italic> (all p&#x02264;0.05) genes and three CpG sites in the promoter region of <italic toggle="yes">C4</italic> (all p&#x0003c;0.05) gene were hypermethylated, while two CpG sites in the gene body of <italic toggle="yes">Il6</italic> (all p&#x02264;0.05) gene and two CpG sites in the promoter region of <italic toggle="yes">Il10</italic> (all p &#x02264;0.05) gene were hypomethylated after 12-weeks of yoga therapy in schizophrenia patients.</p></sec><sec id="sec0059"><title>Conclusions</title><p>Our findings provide important insights into the mode of action of yoga therapy in schizophrenia. This study for the first time reports the epigenetic effects of yoga therapy on immune-inflammatory pathway in schizophrenia.</p></sec><sec id="sec0060"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>